Photo of Cindy  Bott, Ph.D.Photo of Cindy  Bott, Ph.D.

Cindy Bott, Ph.D.

Partner

Education

University of Cincinnati College of Law, J.D.
  • Order of the Coif; Dean’s Honor List; Charles A. Corry Prize for Corporate Law; West Publishing Prize for Civil Procedure; Timothy Walker Founder's Scholarship (Full Merit Scholar)
  • University of Cincinnati Law Review, Student Articles Editor (1998-1999) and Associate Member (1997-1998)
University of Michigan, Ph.D.
  • Cellular and Molecular Biology
  • Regents Fellowship; Cancer Center Fellowship; Abraham H. Grant Scholastic Award
Michigan State University, B.S.
  • Biochemistry
  • with high honors

Prior Employment

  • Brinks Hofer Gilson & Lione, Counsel, Ann Arbor, MI, 2007-2009
  • Pfizer Inc., Corporate Counsel, Ann Arbor, MI, 2002-2007
  • Procter & Gamble, Counsel, Cincinnati, OH, 1999-2002
  • Institute of Cancer Research, Chester Beatty Laboratories, Postdoctoral Fellow, London, England, 1992-1995

Bar Admissions

Professional Affiliations

American Bar Association

American Intellectual Property Law Association

Intellectual Property Owners Association

MichBio

Women in Bio

Overview
Experience
Community
News & Resources

Overview

Dr. Cindy Bott focuses her practice on the biotechnology and pharmaceutical industries advising clients on a wide range of intellectual property issues. She helps clients to obtain robust patents in the U.S. and worldwide, and to develop effective global patent strategies. She possesses a technical background in biochemistry, cell biology, molecular biology, and immunology and has extensive in-house experience as patent counsel for Pfizer and Procter & Gamble Pharmaceuticals.  

  • Holds Ph.D. in Cell and Molecular Biology from the University of Michigan
  • Prosecutes global intellectual property portfolios
  • Manages global patent portfolios and provides patent filing strategies
  • Counsels large and small companies regarding product life-cycle management and freedom-to-operate
  • Advises clients regarding Hatch-Waxman issues such as Orange Book listings and patent term extension
  • Negotiates, drafts and reviews agreements related to intellectual property transactional matters
  • Advises and helps position small companies for partnering with large biotech and pharmaceutical companies
  • Renders legal opinions on patent validity and/or patent non-infringement
  • Conducts intellectual property due diligence for transactional matters

Experience

  • Obtained numerous U.S. Patents, including:
    • U.S. Patent No. 10,106,618: Anti-CD40L antibodies and methods for treating CD40L related diseases or disorders.
    • U.S. Patent No. 10,087,464: Compositions and Methods for Delivering Nucleic Acid to a Cell
    • U.S. Patent No. 10,028,935: Stabilized Multi-Functional Antioxidant Compounds and Methods of Use
    • U.S. Patent No. 10,028,926: Methods of Reducing Risk of Cardiovascular Disease
    • U.S. Patent No. 9,849,104: Treatment of NASH with Gemcabene
    • U.S. Patent No. 9,593,079: Stabilized Multi-Functional Antioxidant Compounds and Methods of Use
    • U.S. Patent No. 9,382,211: Stabilized Multi-Functional Antioxidant Compounds and Methods of Use
    • U.S. Patent No. 9,044,459: Method for the treatment of Neurodegenerative Diseases
    • U.S. Patent No. 8,846,761: Method for Treating Pancreatitis
    • U.S. Patent No. 8,771,931: Perfusion Culture Method and Perfusion Culture Device for Organ or Tissue
    • U.S. Patent No. 8,653,026: Treatment of Type 2 Diabetes with FTY720
    • U.S. Patent No. 8,557,835: Statin-Carboxyalkylether Combinations
    • U.S. Patent No. 8,435,514: Method for the treatment of Neurodegenerative Diseases
    • U.S. Patent No. 8,080,567: EP2 receptor agonists
    • U.S. Patent No. 7,189,689: Apolipoprotein A-1 agonists and their use to treat dyslipidemic disorders
    • U.S. Patent No. 7,045,653: Neural endopeptidase inhibitors
    • U.S. Patent No. 6,773, 896: Method for direct measurement of coagulation factor VIIa activity in plasma
    • U.S. Patent No. 6,750,194: Methods of identifying compounds for regulating muscle Mass or function using vasoactive peptide receptors
    • U.S. Patent No. 6,723,499: Method for identifying inhibitors of dual substrate enzymes
    • U.S. Patent No. 6,670,140: Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
    • U.S. Patent No. 6,469,000: 1,3-diheterocyclic metalloprotease inhibitors 
    • U.S. Patent No. 6,316,207: Mouse cardiac muscle cell line HL-1
    • U.S. Patent No. 6,248,554: DNA sequence coding for a BMP receptor
    • U.S. Patent No. 6,225,483: Medium chain length PHA copolymer and process for producing same
    • U.S. Patent No. 6, 162,818: 2-imidazolinylaminoindole compounds useful as alpha-2adrenoceptor agonists
    • U.S. Patent No. 6,117,871: 6-(2-imidazolinylamino) quinoxaline compounds useful as alpha-2adrenoceptor agonists
  • Prosecuted numerous patent applications, including:
    • PCT/US2018/034172 (Not yet published): Therapeutic Anti-CD40 Ligand Antibodies.
    • PCT/US2018/025700 (WO 2018/187215): Bispecific 4-1BB Agonist Molecules
    • PCT/US2018/021093 (WO 2018/165120): Effect of Carboxyalkylethers on Obesity Symptoms and Lipodystropy
    • PCT/US2018/020381 (WO 2018/160794): EPHA2-Targeted Docetaxel-Generating Liposomes in Combination with an Agent that Impedes Regulatory T Cell Activity for Treating Cancer
    • PCT/US2018/016100 (WO 2018/144514): TNF Superfamily Fusion Polypeptides
    • U.S. Application No. 16/125,317: Anti-CD40L antibodies and methods for treating Anti-CD40L related diseases or disorders. (ALSTDI)
    • U.S. Application No. 16/085,508:Treating Ephrin Receptor A2 (EPHA2) Positive Cancer with Targeted Docetaxel-Generating Nano-Liposome Compositions
    • U.S. Application No. 16/085,486: Nanoliposomal Targeting of Ephrin Receptor A2 (EPHA2) and Related Diagnostics
    • U.S. Application No. 16/025,503: Compositions and Methods for Delivering Nucleic Acid to a Cell
    • U.S. Application No. 16/024,288: Methods of Reducing Risk of Cardiovascular Disease
    • U.S. Application No. 15/622,329 (US 2017/0340656): Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic Agents
    • U.S. Application No. 15/424,620 (US 2017/0172955): Treatment of Mixed Dyslipidemia
    • U.S. Application No. 15/814,557 (US 2018/0133177): Treatment of NASH with Gemcabene
    • U.S. Application No. 15/956,232 (US 2018/0250251): Treatment of Patients with Familial Hypercholesterolemia on Lipid-Lowering Therapy
    • U.S. Application No. 15/460,280 (US 2018/0021294): Ephrin Receptor A2 (EHPA2)-Targeted Docetaxel-Generating Nano-Liposome Compositions
    • U.S. Application No. 15/445,118 (US 2017/0246133): Treatment of Patients with Homozygous Familial Hypercholesterolemia on Lipid Lowering Therapy
    • U.S. Application No. 15/321,905 (US 2017/0130214): Acinetobacter Lysins

Community

ABA Judicial Intern Opportunity Program

  • Volunteer

News & Resources

News

Publications

Seminars & Events